These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34522200)

  • 21. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of
    Nasab RR; Mansourian M; Hassanzadeh F; Shahlaei M
    Res Pharm Sci; 2018 Dec; 13(6):509-522. PubMed ID: 30607149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Some novel hybrid quinazoline-based heterocycles as potent cytotoxic agents.
    Malekzadeh M; Dadkhah S; Khodarahmi GA; Asadi P; Hassanzadeh F; Rostami M
    Res Pharm Sci; 2022 Feb; 17(1):22-34. PubMed ID: 34909041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, molecular properties and comparative docking and QSAR of new 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetic acid derivatives as possible anticancer agents.
    Elhenawy AA; Al-Harbi LM; El-Gazzar MA; Khowdiary MM; Moustfa A
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Jul; 218():248-262. PubMed ID: 31003050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological activity, quantitative structure-activity relationship analysis, and molecular docking of xanthone derivatives as anticancer drugs.
    Miladiyah I; Jumina J; Haryana SM; Mustofa M
    Drug Des Devel Ther; 2018; 12():149-158. PubMed ID: 29391779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinazoline based 1,3,5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: Design, synthesis, docking, and QSAR study.
    Pathak P; Naumovich V; Grishina M; Shukla PK; Verma A; Potemkin V
    Arch Pharm (Weinheim); 2019 Sep; 352(9):e1900053. PubMed ID: 31380598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
    Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
    Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, Biological Evaluation, 2D-QSAR, and Molecular Simulation Studies of Dihydropyrimidinone Derivatives as Alkaline Phosphatase Inhibitors.
    Altaf R; Nadeem H; Iqbal MN; Ilyas U; Ashraf Z; Imran M; Muhammad SA
    ACS Omega; 2022 Mar; 7(8):7139-7154. PubMed ID: 35252705
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Hammoudi NE; Benguerba Y; Attoui A; Hognon C; Lemaoui T; Sobhi W; Benaicha M; Badawi M; Monari A
    J Biomol Struct Dyn; 2022 Feb; 40(2):886-902. PubMed ID: 32948119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, biological evaluation, and computational studies of some novel quinazoline derivatives as anticancer agents.
    Emami L; Khabnadideh S; Faghih Z; Farahvasi F; Zonobi F; Gheshlaghi SZ; Daili S; Ebrahimi A; Faghih Z
    BMC Chem; 2022 Nov; 16(1):100. PubMed ID: 36419100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Metabolic Reactivity Studies of Quinazoline Derivatives for their Anti-EGFR Activity Against Tumor Angiogenesis.
    Shah AA; Ahmad S; Yadav MK; Raza K; Kamal MA; Akhtar S
    Curr Med Chem; 2024; 31(5):595-619. PubMed ID: 36892124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D-QSAR and docking studies on ursolic acid derivatives for anticancer activity based on bladder cell line T24 targeting NF-kB pathway inhibition.
    Yadav D; Nath Mishra B; Khan F
    J Biomol Struct Dyn; 2019 Sep; 37(14):3822-3837. PubMed ID: 30261824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into the EGFR SAR of N-phenylquinazolin-4-amine-derivatives using quantum mechanical pairwise-interaction energies.
    Simeon S; Jongkon N; Chotpatiwetchkul W; Gleeson MP
    J Comput Aided Mol Des; 2019 Aug; 33(8):745-757. PubMed ID: 31494804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure based design and anti-breast cancer evaluation of some novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor inhibitors.
    Haghighijoo Z; Rezaei Z; Jaberipoor M; Taheri S; Jani M; Khabnadideh S
    Res Pharm Sci; 2018 Aug; 13(4):360-367. PubMed ID: 30065769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
    Davis GD; Vasanthi AH
    Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies.
    Abbasi-Radmoghaddam Z; Riahi S; Gharaghani S; Mohammadi-Khanaposhtanai M
    Mol Divers; 2021 Feb; 25(1):263-277. PubMed ID: 32140890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico drug design of inhibitor of nuclear factor kappa B kinase subunit beta inhibitors from 2-acylamino-3-aminothienopyridines based on quantitative structure-activity relationships and molecular docking.
    Wang JL; Li L; Hu MB; Wu B; Fan WX; Peng W; Wei DN; Wu CJ
    Comput Biol Chem; 2019 Feb; 78():297-305. PubMed ID: 30605855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hybrid Quinazoline 1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study.
    Pathak P; Rimac H; Grishina M; Verma A; Potemkin V
    ChemMedChem; 2021 Mar; 16(5):822-838. PubMed ID: 33155373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.